Lewy Body Disease vs Alzheimer’s: Key Symptoms and Differences

Catherine Laborde has passed away after battling Lewy body disease, a condition often mistaken for Alzheimer’s due to similar symptoms. However, the two illnesses present notable differences and distinct warning signs that are important to recognize.

A Silent and Elusive Disease

Every year, World Lewy Body Disease Day attempts to shine a spotlight on a largely hidden reality. While it attracts far less attention than Alzheimer’s, this form of neurodegenerative dementia impacts an estimated 250,000 people in France alone. Despite such numbers, a lack of public awareness leads to considerable underdiagnosis—only around two-thirds of cases are properly identified. A notable example: former TF1 weather presenter Catherine Laborde, who publicly revealed her battle with the disease in 2014, before passing away last year at the age of 73.

Complex Symptoms Blur the Lines

Detecting Lewy body disease (LBD) is no straightforward task. Its symptoms often mirror those of other neurodegenerative illnesses, complicating matters for both patients and specialists. The French association France Alzheimer points out that LBD was described in detail only in the 1990s and involves abnormal deposits of alpha-synuclein—a protein that disrupts brain regions critical for thought and movement.

Distinguishing LBD from Alzheimer’s can be challenging, as both conditions share cognitive and memory-related difficulties. However, several warning signs set LBD apart:

• Motor problems such as stiffness, slowed movement, or even falls—typically milder than in Parkinson’s disease;
• Persistent visual or auditory hallucinations that patients recognize as unreal;
• Sleep disturbances and mood disorders, sometimes accompanied by depression;
• Pronounced fluctuations in blood pressure and cardiac regulation.

Patients may also struggle with logical reasoning or multitasking. The course of this dementia varies considerably between individuals.

No Cure: Only Symptom Management

Arriving at a definitive diagnosis is rarely swift. Physicians must exclude other possibilities through a battery of examinations—ranging from brain scans such as DAT scans and MRIs to sleep studies and cardiac scintigraphy. Even then, clarity takes time.

Treatments remain limited: while no cure exists for LBD—which typically emerges after age fifty—medical teams focus on mitigating symptoms. Cholinesterase inhibitors are prescribed to slow cognitive decline; anti-Parkinsonian drugs like levodopa can aid mobility but must be used cautiously; clozapine may help manage hallucinations, while serotonin reuptake inhibitors target depressive symptoms.

Towards Greater Awareness

Several factors explain why care remains suboptimal:
• LBD remains poorly understood among both the general public and many healthcare professionals.
• Diagnostic tools are imperfect, prolonging uncertainty for families.
• Treatments offer only partial relief.

In light of these hurdles, strengthening education on lesser-known neurodegenerative diseases seems essential—not just for caregivers but for society at large—if timely diagnosis and improved quality of life are ever to become realities for those affected by Lewy body disease.